Remote Video Consultation for Quality of Life Assessment in Patients Hospitalised After COVID-19 Infection (TELECOVID)

August 24, 2021 updated by: Groupe Hospitalier du Havre

Remote Evaluation of Quality of Life and Functional Capacities in Patients Hospitalised for COVID-19: a Prospective Observational Study

Around 90.000 patients have been hospitalised due to COVID-19 infection in France between March 1st and June 15th; 19% of those requiring intensive care. Approximately 80% of these patients have been discharged home by September 30th. Nonetheless, COVID-19 infection along with intensive care consequences are very likely to impede those patients quality of life and functional capacities.

This study aims to describe the quality of life outcomes and functional capacities of COVID-19 survivors, at least 6 months after primary care hospital discharge.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

157

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Normandie
      • Montivilliers, Normandie, France, 76290
        • Groupe Hospitalier Du Havre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

COVID-19 adults patients hospitalised at Le Havre hospital between March 1st and May 11th

Description

Inclusion Criteria:

  • Adult patient
  • COVID-19 hospitalisation at Le Havre hospital between March 1st and May 11th
  • Non-opposition during first phone contact

Exclusion Criteria:

  • Guardianship
  • Juvenile patients
  • Pregnancy
  • Inability to communicate
  • Cognitive disorders
  • Deceased patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health-related quality of life
Time Frame: 10 to 12 months after hospital discharge during remote video consultation
Measured with the Short-Form health survey (SF-36) scale (score ranging form 0 (worst score) to 100 (best score) per item)
10 to 12 months after hospital discharge during remote video consultation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional capacity
Time Frame: 10 to 12 months after hospital discharge during remote video consultation
One-minute Sit-to-stand test
10 to 12 months after hospital discharge during remote video consultation
Independency
Time Frame: 10 to 12 months after hospital discharge during remote video consultation
KATZ score (ranging 0 (fully dependent) to 6 (fully independent))
10 to 12 months after hospital discharge during remote video consultation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2021

Primary Completion (Actual)

March 20, 2021

Study Completion (Actual)

June 15, 2021

Study Registration Dates

First Submitted

January 14, 2021

First Submitted That Met QC Criteria

January 14, 2021

First Posted (Actual)

January 19, 2021

Study Record Updates

Last Update Posted (Actual)

August 27, 2021

Last Update Submitted That Met QC Criteria

August 24, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Subscribe